NCT06345885View on ClinicalTrials.gov

Immunogenicity and Safety of One Dose of HPV Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
Human Papillomavirus Vaccines
Interventions
BIOLOGICAL

HPV vaccine

Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months

Trial Locations (1)

350012

Fujian Provincial Center for Disease Control and Prevention, Fuzhou

All Listed Sponsors
lead

Xiamen Innovax Biotech Co., Ltd

INDUSTRY